BlueMountain Capital Management LLC acquired a new stake in shares of Stemline Therapeutics Inc (NASDAQ:STML) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 8,531 shares of the biopharmaceutical company’s stock, valued at approximately $137,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Stemline Therapeutics during the second quarter valued at approximately $398,000. BlackRock Inc. increased its stake in shares of Stemline Therapeutics by 11.8% during the first quarter. BlackRock Inc. now owns 1,571,426 shares of the biopharmaceutical company’s stock valued at $24,043,000 after acquiring an additional 165,245 shares during the period. Knott David M grew its position in Stemline Therapeutics by 20.0% in the first quarter. Knott David M now owns 90,000 shares of the biopharmaceutical company’s stock worth $1,377,000 after buying an additional 15,008 shares during the last quarter. venBio Select Advisor LLC acquired a new position in Stemline Therapeutics in the first quarter worth approximately $8,022,000. Finally, Citadel Advisors LLC acquired a new position in Stemline Therapeutics in the first quarter worth approximately $8,948,000. Institutional investors and hedge funds own 67.16% of the company’s stock.
Stemline Therapeutics stock opened at $16.50 on Wednesday. The company has a market capitalization of $535.87 million, a price-to-earnings ratio of -5.82 and a beta of 0.30. Stemline Therapeutics Inc has a 1 year low of $10.20 and a 1 year high of $20.55.
STML has been the topic of several recent research reports. ValuEngine upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 14th. HC Wainwright restated a “buy” rating on shares of Stemline Therapeutics in a research report on Monday, June 18th. BidaskClub upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. Finally, Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research report on Friday, June 15th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Stemline Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $30.00.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Read More: Stock Split
Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics Inc (NASDAQ:STML).
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.